- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01758874
Study to Explore the Effect of Lowering Blood Viscosity in Patients With Treatment-resistant Critical Limb Ischemia (CLI-PH)
Phase 2 Study to Explore the Effect of Lowering Blood Viscosity in Patients With Treatment-resistant Critical Limb Ischemia
PAD is caused by an increased flow resistance in atherosclerotic ischemic limbs. The investigators hypothesize that reducing blood viscosity (through controlled phlebotomy), thereby increasing the deformability of red blood cells, should reduce the flow resistance and improve tissue perfusion leading to improved clinical function and a reduction in symptoms.
Preliminary data demonstrates that phlebotomy causes a measurable change in blood viscosity as measured by the home-made rheologic method.
To evaluate the effectiveness of changes in blood viscosity, obtained through controlled phlebotomy, as a therapy to improve functional status associated with atherosclerotic ischemic limbs in pre-amputation patients.
Study Overview
Detailed Description
The first study is a pilot study and will act as proof of principle. This first study will include 20 patients divided into 2 groups on the basis of a randomized controlled trial: 10 patients in the control group receiving conventional treatment and 10 patients receiving therapeutic phlebotomy to lower blood viscosity. The objective is to evaluate the effect of controlled phlebotomy in patients with Grade 3, Category 5 or 6 chronic critical limb ischemia having tissue loss on Rutherford classification (Fontaine stage IV), end-stage peripheral vascular disease resistant to maximal medical therapy and where revascularization therapy (both percutaneous and surgical) has either proved insufficient or is contra-indicated or declined by the patient, usually resulting in amputation.
The primary outcome parameters will be: the salvage rate of the limb as compared with the salvage rate of the limb with conventional therapy.
Objective classification of improvement in perfusion of the distal extremities using ankle-brachial index (ABI), visual analogue pain scale, and photos.
Subjective classification of improvement in pain scale on critical limbs.
The relationship between alteration in outcome parameters (i.e., the end point is a reduced amputation rate) and blood viscosity will be evaluated as measured by the home-made rheologic methods.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 134-060
- Seoul Veterans Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects should have diagnosed Rutherford classification Grade 3, Category 5 or 6 (Fontaine stage IV) treatment-resistant chronic critical limb ischemia having tissue loss, not relieved by maximal medical therapy and they should have exhausted or not be candidates for surgical (other than heart transplant) or percutaneous intervention
- Male
- Age: 18 to 80 years
- Current non-smokers
- BMI >19
- Estimated 6 month survival rate >90%
- Concomitant stable medications will be allowed.
- If the subjects have coronary artery disease established by history, angina pain, EKG, Lab including Troponin I, creatine kinase, lactate dehydrogenase, Echocardiography, Thallium scan or coronary angiography, the subjects should have established a classification of coronary artery involvement by coronary angiography or other procedure with similar precision.
Exclusion Criteria:
- Anemia
- Low blood pressure (systolic < 120 mmHg)
- Baseline hematocrit < 30
- Initial whole blood viscosity measurements below 15 miliPoiseille
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Non phlebotomy group (control group)
• This control group is the patients who had Rutherford classification Grade 3, Category 5 or 6 (Fontaine stage IV) treatment-resistant chronic critical limb ischemia having tissue loss. They were treated with conventional standard treatment including revascularization operative procedure if feasible, maximum medical treatment with anticoagulation (heparin, low molecular weight heparin, etc), acetylsalicylic acid, cilostazol, and prostaglandin E1, dextran, and pain analgesia with opioid, and finally major amputation. We records all control arms' amputation, day to amputation, mortality, etc. We will compare amputation and mortality between control and treatment groups. Non phlebotomy arm has no phlebotomy treatment. |
|
Experimental: PH (study group)
The patients will be pre-amputation and have Rutherford classification Grade 3, Category 5 or 6 (Fontaine stage IV) treatment-resistant chronic critical limb ischemia having tissue loss. Procedures for therapeutic phlebotomy
They were treated both phlebotomy and conventional standard management including surgery, medication, amputation, etc. We will compare amputation and mortality between control and study groups. |
repeated phlebotomy for 4 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major amputation rate (limb salvage rate)
Time Frame: 5 year follow-up period
|
The rate of lower limb major amputation (limb salvage rate) was measured in both study arms, during 5 year follow-up period. They would be the evidences of phlebotomy treatment directly. |
5 year follow-up period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time-to-major amputation
Time Frame: 5 year follow-up period
|
During 5 year follow-up period, we measured the time-to-major amputation between the two groups, phlebotomy study group and control group. They would be the evidences of phlebotomy treatment directly. |
5 year follow-up period
|
Mortality rate
Time Frame: 5 year follow-up period
|
During 5 year follow-up period, we measured the mortality rate as a final result of a treatment and major amputation between the two groups, phlebotomy study group and control group. They would be the evidences of phlebotomy treatment directly. |
5 year follow-up period
|
Blood viscosity measurements
Time Frame: Conducting study periods (4 weeks)
|
The relationship between alteration in outcome parameters (i.e., the end point is a reduced amputation rate) and blood viscosity will be evaluated as measured by the home-made rheologic methods. Evaluate blood viscosity measurements with the home-made rheologic method as a monitor of and marker for the clinical effectiveness of therapeutic phlebotomy in patients with Rutherford classification Grade 3, Category 5 or 6 (Fontaine stage IV) treatment-resistant chronic critical limb ischemia having tissue loss. |
Conducting study periods (4 weeks)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
VA pain scale
Time Frame: Conducting study periods (4 weeks)
|
After 4 weeks phlebotomy, we measured and confirmed the VA pain scale improvement or not in study group.
They would be the evidences of phlebotomy treatment indirectly.
|
Conducting study periods (4 weeks)
|
Ankle-Brachial Index
Time Frame: Conducting study periods (4 weeks)
|
After 4 weeks phlebotomy, we measured and confirmed the ABI improvement or not in study group.
They would be the evidences of phlebotomy treatment indirectly.
|
Conducting study periods (4 weeks)
|
Complete wound healing
Time Frame: Conducting study periods (4 weeks)
|
After 4 weeks phlebotomy, we measured and confirmed the complete wound healing (no more discharge from wound and complete epithelialization) between two groups.
They would be the evidences of phlebotomy treatment directly.
|
Conducting study periods (4 weeks)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Doosang Kim, M.D.,Ph.D., Seoul Veterans Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2006-19
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Critical Limb Ischemia
-
R3 Vascular Inc.RecruitingCritical Limb Ischemia | Critical Lower Limb Ischemia | Critical Limb-Threatening IschemiaAustralia
-
Fudan UniversityActive, not recruiting
-
University Health Network, TorontoUnknown
-
Changi General HospitalCompletedCritical Limb IschemiaSingapore
-
AnGes USA, Inc.TerminatedCritical Limb IschemiaUnited States, France, Belgium, Canada, Poland, Finland, Denmark, Netherlands, Hungary, Italy, Sweden
-
R-BioPusan National University HospitalCompletedCritical Limb IschemiaKorea, Republic of
-
Pharmicell Co., Ltd.Withdrawn
-
Lifecells, LLC.CompletedCritical Limb IschemiaUnited States
-
Neuromed IRCCSUnknown
Clinical Trials on phlebotomy
-
Georgetown UniversityNova Southeastern UniversityUnknown
-
The University of Texas Health Science Center,...Completed
-
The University of Texas Health Science Center,...Recruiting
-
Leiden University Medical CenterRecruiting
-
ImmuniconUnknownNeoplasm Metastasis | Colorectal CancerUnited States
-
University of Colorado, DenverCompletedRespiratory Tract Infections | Down Syndrome | Polyendocrinopathies, Autoimmune | AutoimmunityUnited States
-
Milton S. Hershey Medical CenterWithdrawnSepsis | Septic Shock | Multiple Organ Dysfunction | Intra-abdominal Sepsis
-
Radboud University Medical CenterUnknown
-
Stanford UniversityEnrolling by invitation
-
Stanford UniversityCompleted